Sure! Here’s the translation into American English:
—
AATec Medical and Northway Biotech have formalized a strategic alliance that promises to revolutionize the treatment of bronchiectasis without cystic fibrosis through the development of an industrial production process for their innovative drug ATL-105. This treatment is based on a recombinant version of alpha-1 antitrypsin and utilizes a multimodal mechanism of action to address various factors triggering this lung disease.
The collaboration between both companies will allow Northway Biotech to apply its extensive experience in the manufacturing of biological products, thereby scaling the production of ATL-105 through the Pichia pastoris expression system. Rüdiger Jankowsky, CEO of AATec, emphasized that this partnership establishes a robust manufacturing process, ensuring consistent quality for both clinical development and commercialization. Jankowsky highlighted that ATL-105 represents a new generation of inhaled biological products, combining antiprotease, anti-inflammatory, and anti-infective properties in a single molecule.
The treatment is administered via inhalation, allowing for rapid and targeted action with minimal systemic exposure. This provides a promising solution for severe respiratory diseases that currently lack adequate treatments. For his part, Vladas Algirdas Bumelis, CEO of Northway Biotech, expressed his enthusiasm for the collaboration with AATec, emphasizing the significance of this development in a context of unmet medical needs and his team’s ability to scale the program efficiently, ensuring quality at every phase.
ATL-105 not only focuses on bronchiectasis without cystic fibrosis but also has significant therapeutic potential for various inflammatory and infectious respiratory conditions, including COPD and ARDS. This versatility is due to its anti-inflammatory, immunomodulatory, and anti-infective properties, which further underscore its importance in the field of pulmonary health.
AATec Medical GmbH is known for its focus on developing products based on alpha-1 antitrypsin for respiratory diseases, while Northway Biotech specializes in the development and manufacture of biopharmaceuticals, excelling in the management of protein-based products and gene therapies. Both organizations position themselves as key players in improving treatments for chronic respiratory diseases, aiming to positively impact the quality of life for millions of patients worldwide.
—
Let me know if you need any further assistance!
via: MiMub in Spanish